Compare McKesson Corporation (MCK) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Plby Group Inc — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: McKesson Corporation is far larger — about 917.5× Plby Group Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Plby Group Inc for 24 Days on average.
| MCK | PLBY | |
|---|---|---|
Market Cap | $108.46B | $118.21M |
Volume | 712,607 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $2.71 |
52-Week Low | $725.17 | $0.98 |
Typical Hold Time | 74 Days | 24 Days |
Enterprise Value | $115.00B | $263.80M |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
PLBY trades at $0.9867, down 3.26% today, amid a bearish technical signal with selling pressure across moving averages. The company reported Q2 2026 EPS of $0.00173, beating expectations, and revenue of $121 million in 2025, with net losses narrowing to $12.67 million. Recent news highlights leadership appointments aimed at driving brand growth. Analyst consensus is 75% buy, but high debt and negative equity pose fundamental risks.
Outlook remains cautious due to persistent losses and leveraged balance sheet, though cost controls and licensing growth offer potential upside. Key risks include execution on profitability, competitive pressures, and sensitivity to consumer spending. Investors should weigh analyst optimism against structural financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
